Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] - Page: 4 RSS

00:00 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 76–100 of 8,100+

Relevant

The FlowMetric Family of Companies

The FlowMetric Family of Companies consist of FlowMetric, Inc. and two additional affiliate companies, FlowMetric Europe, S.p.A. and FlowMetric Diagnostics, Inc. FlowMetric, Inc. and FlowMetric Europe, S.p.A., founded in 2010 and 2013 respectively, are niche contract research organizations (CROs), focused on providing polychromatic flow cytometry and cell ...


Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new approach to treat cancer referred to as in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. These products, w...

Advaxis, Inc. 

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based stra...


Unum Therapeutics Inc.

Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeut...

Rigontec

Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach. Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity...

Ribi ImmunoChem Research Incorporated

Ribi ImmunoChem Research Inc., is engaged in the development of biopharmaceutical products that stimulate theimmune system to generate a cascade of natural agents and signals to prevent and treat human disease. Ribi immunostimulants can be combined with disease-specific antigens which may direct the immune system to respond to a particular cancer or infectious disease or can be used to modulate th...

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

Heat Biologics, Inc.

Heat Biologics (www.heatbio.com) (“Heat”) is a clinical-stage company immunotherapy company focused on developing its novel off-the-shelf “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) therapeutic vaccines to combat a wide range of cancers and other diseases. Heat’s ImPACT Therapy effectively reprograms tumor cells to “pump o...

Atox Bio

Established in 2003, Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by an excessive inflammatory response. Atox Bio focuses on novel modulators of the immune response that act broadly to attenuate excessive cytokine responses underlying disease, with therapeutic applications ranging from infectious to in...

DecImmune Therapeutics

DecImmune Therapeutics was founded by Michael Carroll PhD (The Immune Disease Institute, Harvard Medical School), and Francis Moore Jr. MD (Brigham and Women’s Hospital, Harvard Medical School). Drs. Moore and Carroll discovered the epitope of non-muscle myocin heavy chain II (“N2”) that becomes exposed on vascular cells during hypoxia. During ...

Vycellix, Inc.

Vycellix, Inc. is a closely-held biotechnology company advancing innovative products designed to enhance cellular therapies, facilitate manufacturing processes and optimize human immune response against disease with a focus on cancers.

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all huma...

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of immune response modifiers for potential use in the treatment of MS and other autoimmune diseases, a range of infectious diseases, certain cancers, and as a novel cellular and humor...

TREM Rx, Inc.

TREM Rx is a biotechnology company with a proprietary technology platform to create and administer highly effective vaccines that are delivered to the upper layers of skin, rather than to deeper layers of skin, subcutaneous tissue, or muscle as conventional vaccines are delivered. The company’s novel approach is based on the discoveries of its scienti...

Point Therapeutics

Point Therapeutics, Inc is a Boston-based biopharmaceutical company dedicated to developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. DPPs are enzymes that appear to regulate several different physiological processes including those involved in tumor growth and host responses to cancer, type 2 diabetes, and immune responses to v...

Coley Pharmaceutical Group

Our proprietary TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease.Coley’s pipeline of TLR Therapeutics includes four clinical-stage products targeting cancer, viral diseases, asthma and allergy:

Immunome

Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are the exact structures created by nature and possess the natural safety and power of the human immune system. The Immunome method is an exclusive, optimized hybridoma process that produces affinity-matured I...

MetrioPharm AG

MetrioPharm AG is a biotech company developing oral drug compounds for the treatment of autoimmune and other inflammatory diseases. MetrioPharm's MP1000 pipeline consists of small molecule immune modulators for unmet medical needs in Immune-Mediated Inflammatory Diseases (IMIDs). MetrioPharm AG was founded in 2007 and is headquartered in Zurich with resear...

TcLand S.A.

Founded in 2002 as a spin-off of INSERM U643/ITERT, one of the first research and transplantation centers in the world, and initially supported by the local incubator Atlanpole, TcLand is a biopharmaceutical company, pioneer in personalised medicine in transplantation and auto-immune diseases. Originally specialised in analysis and monitoring of T cell immune responses, the company develops now sp...

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes ...

Inimex Pharmaceuticals Inc.

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex’ technology platform will yield novel prophylactic and therapeutic agents which will have a significant impact on management of a wide range of disease indications. Inimex...

Commense, Inc.

Commense, Inc., an affiliate of PureTech Health (LSE: PRTC), is developing interventions for pediatric and maternal health based on a deep understanding of the microbiome and its fundamental role as the foundation for the development of immune tolerance. Commense is working with some of the world’s leading microbiome scientists, physicians, and resear...

Avant Diagnostics, Inc.

Avant Diagnostics, Inc. is a medical diagnostic technology company that specializes in large panel biomarker screening. Our first test, OvaDx®, developed in conjunction with Arrayit Corporation (OTCQB: ARYC), detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system i...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks